SCHEMBL1724539

SCHEMBL1724539

CCOC(=O)c1cc(Oc2ccc3c(c2)CCS3(=O)=O)c2cn(CC)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCK P35557 11/20 0.46
MAPT P10636 4/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
JMJD6 Q6NYC1 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1724540 0.91 GCK (0.46) GCKMAPTTP53THRBJMJD6
SCHEMBL1724129 0.90 GCK (0.46) GCKJMJD6GPR119ALDH1A1NPSR1
SCHEMBL1724761 0.81 GCK (0.46) GCKGPR119LMNAALDH1A1NPSR1
SCHEMBL1725541 0.79 GCK (0.67) GCKMAPTALDH1A1GAA
SCHEMBL12040297 0.77 GCK (0.55) GCKJMJD6
SCHEMBL9989524 0.74 GCK (0.59) GCKRAB9A
SCHEMBL1724799 0.74 HSD17B2 (0.47) GCKMAPTTP53THRBJMJD6
SCHEMBL1724764 0.73 GCK (0.53) GCKMAPTNPC1ALDH1A1GAA
SCHEMBL1727598 0.71 GCK (0.57) GCK
SCHEMBL1724132 0.71 CYP2C19 (0.50) MAPTJMJD6NPC1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406230-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS Pfizer Inc. (US) 2012-01-18 EP disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators CORBETT JEFFREY W (US) 2011-12-29 US disclosed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 WO disclosed
WO-2010103438-A1 SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS PFIZER INC. (US) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319379-A1 Substituted Indazole Amides And Their Use As Glucokinase Activators GCKR, GCK, GALK1 GCK 2/4885MAPT 2946/4885TP53 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.